H2020Индивидуална стипендия2021–2023

NEUROCURE · A novel multi-functional nanocomposites against Parkinson’s disease for the protection and regeneration of dopamine neurons with anti alpha-Synuclein aggregation properties.

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2021-09-01 → 2023-09-16
Финансиране от ЕС: 190 681 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Наночастици с целеви пептиди се тестват за транспортиране на протеина CDNF през кръвно-мозъчната бариера. Това може да помогне за защита и възстановяване на допаминовите неврони при болестта на Паркинсон, без да е необходима сложна операция на мозъка.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

A novel multi-functional nanocomposites against Parkinson’s disease for the protection and regeneration of dopamine neurons with anti alpha-Synuclein aggregation properties.

Parkinson’s disease (PD) is the second most common neurodegenerative disorder that has affected over 10 million people around the world. PD is characterized by progressive degeneration of nigrostriatal dopamine neurons in the substantia nigra. PD progression leads to severe movement disorders and non-motor symptoms. Currently, PD treatment strategies are mostly based on dopamine replacement medicines that temporarily alleviate the symptoms. However, none of the available treatment schemes has shown an ability to slow down the progression of neurodegeneration. Thus, there is an urgent need for novel disease-modifying PD therapies. Preclinical studies have shown that neurotrophic factors have ability to support neuronal functions and reverse neurodegeneration. Therefore, NTFs could not only protect remaining dopamine neurons but also stimulate their regeneration and capacity to make up for already lost cells. One of the most potent NTFs for PD therapy so far is the cerebral dopamine neurotrophic factor (CDNF). However, despite great potential, CDNF does not pass through the blood-brain barrier (BBB) and requires complicated stereotactic brain surgery to administer. Therefore, there is a great need for the development of efficient systemic CDNF delivery methods to avoid intracranial surgery. The current project aimed to develop new and effective methods for CDNF delivery to the brain by utilizing nanotechnology and molecular biology. Specifically, novel nanoparticles functionalized with brain-targeting (homing) peptides and loaded with CDNF were developed and the ability to rescue dopamine neurons was tested. In addition, the ability to penetrate through the BBB was analyzed. Another delivery approach was based on a direct fusion of CDNF with brain-targeting peptides. These novel approaches in CDNF delivery to the brain bring us closer to the non-invasive treatment of PD to help over 10 million people worldwide. Please also see our Youtube video introducing the project: https://youtu.be/6BDo1jcgxBc

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Parkinson’s disease (PD) is the second most common neurodegenerative disorder that is characterised by progressive loss of dopamine neurons and abnormal intra-neuronal accumulation of protein α-synuclein (αS). None of the available treatments have shown ability to slow down the progression of the neurodegeneration. One of the therapeutically potent approaches to combat PD is neurotrophic factor (NTF)-based therapies. Delivery of NTFs to the brain shows a notable therapeutic potential due to the ability to stop and reverse neurodegeneration in animal models. The most potent NTFs for PD therapy so far are CDNF and GDNF that have been recently studied in clinical trials on PD patients. Despite of the promising results, CDNF and GDNF does not pass through the blood brain barrier (BBB) and should be delivered to the brain through a risky microsurgery. Thus, there is a great need for an effective method that can deliver CDNF/GDNF through the BBB avoiding intracranial surgery. Another promising strategy for curing PD is based on αS clearance and control of its pathological aggregation and propagation. Our preliminary results showed that beta-casein coated AuNPs have great capacity to reduce αS aggregation and can be used to deliver NTFs to the brain. This proposal combines nanomedicine and molecular neurobiology to develop multi-functional AuNP-based medicine against PD that will positively impact the disease progression through mitigation of the parthenogenesis associated with αS and support the survival of dopamine neurons by CDNF/GDNF delivery to the brain. The applicant will get training needed for his future independent research career through hands-on training in the top scientific laboratories and by managing the highly innovative research at the interface of different disciplines connecting two excellent scientists: Prof. Saarma, a world leading molecular neurobiologist and Prof. Teesalu, an expert in homing peptides.

Оригинален текст от CORDIS (на английски).

Участници

HELSINGIN YLIOPISTO · HelsinkiКоординаторФинландия